Core Insights - PROCEPT BioRobotics Corporation hosted its 2026 Investor Day to discuss market opportunities, long-term strategy, growth goals, and financial guidance for 2026-2027 [1] Market Opportunity - The company highlighted a significant underpenetrated market in Benign Prostatic Hyperplasia (BPH), with 40 million men in the U.S. affected [2][5] - PROCEPT has treated over 125,000 patients, showcasing a strong foundation of technology and clinical evidence [2][5] Strategic Focus - The CEO emphasized a shift towards establishing leadership in BPH through a comprehensive solution that provides durable symptom relief and lower adverse outcomes [3] - Future strategies will include growth in Aquablation procedures, disciplined pricing, commercial execution, patient education, and international expansion [3] Financial Guidance - The company projects annual revenue growth of 27% to 33% for 2026, with procedure growth expected to be between 39% and 48% [9] - For 2027, annual revenue growth is anticipated to be 25% to 30% [9] - Gross margins are expected to improve to 65% in 2026 and 68% to 70% in 2027 [9] - Positive adjusted EBITDA is expected in Q4 2026, with a gain of $25 to $30 million projected for 2027 [9]

Core Insights - PROCEPT BioRobotics Corporation reported a strong fourth quarter for 2025, achieving its highest procedure volume to date with approximately 12,200 procedures and selling 65 new systems, indicating robust growth and operational improvements [2][12]. Financial Performance - Total revenue for Q4 2025 was $76.4 million, a 12% increase compared to Q4 2024. U.S. revenue was $66.6 million, reflecting a 10% growth year-over-year, primarily driven by increased handpiece revenue [4][12]. - U.S. handpiece and consumable revenue reached $34.0 million, up 16% from the previous year, while system revenue remained flat at $27.6 million [4][12]. - The gross margin for Q4 2025 was 61%, down from 64% in the prior year, mainly due to lower-than-expected U.S. consumable revenue and a one-time cost related to a voluntary field action [5]. - Operating expenses for Q4 2025 were $77.4 million, an increase of 22% from $63.4 million in Q4 2024, reflecting investments in commercial expansion and R&D [6][9]. - The net loss for Q4 2025 was $29.8 million, compared to a loss of $18.9 million in Q4 2024. Adjusted EBITDA was a loss of $19.0 million, worsening from a loss of $10.3 million in the prior year [7][10]. Annual Overview - For the full year 2025, total revenue was $308.1 million, a 37% increase from 2024, driven by U.S. revenue growth from system placements and handpiece sales [8]. - The gross margin for the full year improved to 64% from 61% in 2024, attributed to better overhead absorption and a favorable revenue mix [8]. - Operating expenses for the full year were $300.1 million, up 28% from $233.7 million in 2024, due to increased sales and marketing expenses [9]. - The net loss for 2025 was $95.6 million, slightly higher than the $91.4 million loss in 2024. Adjusted EBITDA loss was $50.2 million, an improvement from a loss of $61.1 million in 2024 [10]. Future Guidance - The company expects 2026 revenue to be between $390 million and $410 million, representing a growth of 27% to 33% compared to 2025. U.S. procedure growth is projected to be between 39% and 48% [11][18]. - The anticipated gross margin for 2026 is approximately 65%, with operating expenses expected to be around $350 million [18]. - The company aims to align handpiece unit sales closely with procedure volumes, which may impact projected handpiece revenue but is expected to be offset by higher handpiece prices [11][18].

Core Insights - PROCEPT BioRobotics is focused on advancing patient care in urology through transformative robotic solutions [3] - The company will present at two investor conferences in March 2026, indicating active engagement with the investment community [1][2] Company Overview - PROCEPT BioRobotics aims to revolutionize the treatment of Benign Prostatic Hyperplasia (BPH) globally by partnering with urologists [3] - The company manufactures the AQUABEAM® and HYDROS® Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to BPH, regardless of prostate size, shape, or surgeon experience [3] - BPH affects approximately 40 million men in the United States, highlighting a significant market opportunity for the company [3] Upcoming Events - The company will participate in the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Health Care Conference [2] - A live webcast of each event will be available on the company's website, with recordings archived for at least 90 days [2] - Specific event details include a fireside chat on March 2 at 11:40 am ET in Boston, MA, and another on March 10 at 8 am ET in Miami, FL [4]

Group 1 - The company, PROCEPT BioRobotics Corporation, will report its financial results for Q4 2025 on February 24, 2026, after market close, followed by a conference call at 4:30 p.m. Eastern Time [1] - An in-person investor day event is scheduled for February 25, 2026, at NASDAQ Headquarters in New York City, starting at 8:00 a.m. Eastern Time, with advance registration recommended [2] - Live webcasts of both the financial results and investor day will be available on the company's website, with recordings archived for at least 90 days [3] Group 2 - PROCEPT BioRobotics aims to revolutionize BPH treatment globally by providing advanced robotic solutions that enhance patient outcomes and deliver value [4] - The company manufactures the AQUABEAM® and HYDROS® Robotic Systems, with the HYDROS system being the only AI-powered technology for Aquablation therapy, designed for effective treatment of lower urinary tract symptoms in men [4] - BPH is the most common prostate disease, affecting approximately 40 million men in the United States [4]

Core Insights - PROCEPT BioRobotics Corporation reported a strong performance with a 43% year-over-year global revenue growth for Q3 2025, driven by increased demand for the HYDROS® Robotic System and Aquablation therapy adoption [3][4]. Financial Performance - Total revenue for Q3 2025 was $83.3 million, a 43% increase compared to Q3 2024 [4][9]. - U.S. revenue reached $73.9 million, reflecting a 42% growth year-over-year, primarily from system sales and increased handpiece revenue [4][9]. - U.S. handpiece and consumable revenue was $44.4 million, up 50% from the previous year, while system revenue was $24.7 million, a 26% increase [4][9]. - International revenue for the quarter was $9.4 million, marking a 53% increase compared to the prior year [4][9]. Gross Margin and Operating Expenses - Gross margin improved to 65% in Q3 2025 from 63% in the prior year, attributed to operational efficiencies despite increased tariff expenses [5]. - Operating expenses rose to $77.2 million from $59.3 million in the prior year, driven by expansion of the commercial organization and increased R&D and administrative expenses [6]. Net Loss and Adjusted EBITDA - The net loss for Q3 2025 was $21.4 million, slightly higher than the $21.0 million loss in Q3 2024 [7]. - Adjusted EBITDA loss improved to $7.4 million from a loss of $12.4 million in the prior year [7][18]. Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and restricted cash totaling $297.3 million [7]. Full Year Guidance - The company maintains its revenue guidance for the full year 2025 at approximately $325.5 million, representing a 45% growth over the previous year [8][9]. - For 2026, the projected revenue is between $410 million and $430 million, indicating a growth of 26% to 32% compared to 2025 [10][9].